Intangible Assets

Proprietary EpiSelect™ Platform: ProMIS leverages its EpiSelect™ computational platform to identify disease-specific epitopes on misfolded proteins, enabling the development of highly selective antibody therapeutics for neurodegenerative diseases. This proprietary technology differentiates ProMIS from peers and underpins its pipeline, supporting potential long-term revenue durability if clinical efficacy is demonstrated.

FDA Fast Track Designation for PMN310: PMN310, the company’s lead candidate for Alzheimer’s disease, received Fast Track designation from the FDA in July 2025, validating the novelty and potential impact of its approach. This regulatory recognition can accelerate development timelines and enhance the asset’s value.

Specialized Intellectual Property Portfolio: ProMIS maintains a focused IP portfolio around its antibody candidates and platform, providing legal barriers to entry for competitors targeting similar misfolded protein epitopes in neurodegenerative diseases.

ProMIS’s intangible assets are anchored by its proprietary EpiSelect™ platform, regulatory recognition, and targeted IP, which collectively provide a strong foundation for competitive differentiation. The durability of these advantages depends on successful clinical outcomes and ongoing IP protection.

Network Effects

Limited Network Effects in Therapeutics: As a clinical-stage biotech, ProMIS’s business model does not inherently benefit from user-driven network effects. Value creation is primarily tied to clinical success and regulatory milestones rather than platform adoption or user base expansion.

Potential for Partnering Synergies: Future collaborations with larger pharmaceutical companies could create indirect network effects through expanded distribution and data sharing, but such effects are not yet realized or material to current valuation.

Pipeline Expansion May Enhance Ecosystem Value: If ProMIS’s platform enables multiple successful candidates across neurodegenerative indications, a modest ecosystem effect could emerge, but this remains contingent on clinical validation.

Network effects are not a primary moat source for ProMIS at this stage. Any future ecosystem value will depend on successful clinical development and strategic partnerships, which are not yet established.

Switching Costs

Potential for High Switching Costs Post-Approval: If PMN310 or other candidates achieve regulatory approval and demonstrate superior safety or efficacy, physicians and patients may face moderate switching costs due to clinical inertia and treatment protocols.

Current Switching Costs Are Minimal: As ProMIS has no approved products, there are currently no switching costs for prescribers or patients. Future switching costs will depend on clinical differentiation and payer adoption.

Switching costs are not material at present but could become moderate if ProMIS’s therapies prove superior and are integrated into standard of care. This factor is not a current moat driver.

Cost Advantage

No Demonstrated Cost Leadership: ProMIS operates as a clinical-stage biotech with high R&D expenses and no commercial scale, limiting any current cost advantage over larger, established peers.

Platform Efficiency Potential: The EpiSelect™ platform may enable more efficient candidate identification and development, but this has not yet translated into lower unit costs or improved margins, as reflected by ongoing operating losses.

ProMIS does not currently possess a cost advantage. Any future efficiency gains from its platform remain unproven and are not a material moat factor at this stage.

Efficient Scale

Niche Focus in Neurodegenerative Diseases: ProMIS targets high-barrier, specialized markets such as Alzheimer’s and ALS, where few therapies exist and incumbents face significant scientific and regulatory hurdles.

Market Entry Barriers Remain High: The complexity of neurodegenerative drug development and regulatory requirements create natural barriers to entry, but these are industry-wide rather than unique to ProMIS.

No Current Commercial Entrenchment: Without approved products or established market share, ProMIS does not yet benefit from efficient scale advantages that deter new entrants.

While ProMIS operates in markets with high entry barriers, it does not yet possess efficient scale advantages. Future entrenchment will depend on successful commercialization and market adoption.

Overall Score

ProMIS Neurosciences demonstrates strong intangible asset potential through its proprietary platform, regulatory recognition, and focused IP. However, the absence of approved products, commercial scale, and network effects limits the durability and breadth of its moat. The company’s competitive position is contingent on clinical success and future commercialization. At present, ProMIS’s moat is moderate and primarily driven by intangible assets, with other factors providing limited support.